Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remestemcel-L-rknd Added to Ruxolitinib for Grade III-IV Steroid-Refractory Acute Graft-Versus-Host Disease
NCT07568535Phase 3Not yet recruiting
- Sponsor
- Mesoblast Ltd
- Start
- Aug 2026
- Primary completion
- Feb 2028
- Modality
- Mesenchymal Stem Cells
01
Overview
A Phase 3 trial of remestemcel-L-rknd in Acute Graft-Versus-Host Disease (aGvHD), sponsored by Mesoblast Ltd. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
remestemcel-L-rknd
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on NCT07568535.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07568535.